ABT-639

DRUG2 trials

Sponsors

AbbVie (prior sponsor, Abbott)

Conditions

Diabetic Neuropathic Pain

Phase 2

A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain

CompletedNCT01345045

AbbVie (prior sponsor, Abbott)Diabetic Neuropathic Pain

Start: 2011-04-30End: 2011-10-31Updated: 2013-01-08

A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy

CompletedNCT01589432

AbbVie (prior sponsor, Abbott)Diabetic Neuropathic Pain

Start: 2012-04-30End: 2012-11-30Updated: 2013-01-03

Related Papers

A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain

Pain2015-06-1289 citations

Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy

Pain2015-05-3078 citations